Breast Cancer

The risk of a second cancer remained high even 30 years after treatment.

Progression-free survival with IMMU-132 increases from an average of 3.5 months to 16.6 months in patients with breast cancer.

Mylan gains global licenses for its biosimilar to trastuzumab (Herceptin).

Improvements in breast cancer patient quality of life and mortality seen over last 30 years.

Scientists discover a metabolic weakness in advanced breast cancer cells.

Adding pertuzumab (Perjeta) to a breast cancer treatment regimen reduced recurrent disease.

Ribociclib plus letrozole shows improved survival in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2) advanced or metastatic breast cancer.

Ribociclib plus letrozole improved progression free survival in patients with HR+/HER2 advanced or metastatic breast cancer.

The FDA has approved Novartis’ Kisqali (ribociclib), in combination with an aromatase inhibitor as initial endocrine-based therapy treatment, for the treatment of breast cancer.

Neoadjuvant chemotherapy decreased recurrence and increased survival in African American patients.

Compounds demonstrate high cancer-killing activity and low-toxicity in non-tumor cell line.

Targeted and individualized breast cancer treatment is viable.

Many patients with stage 1 and 2 breast cancer are administered aggressive chemotherapy.

Patients with early-stage breast cancer may not need aggressive treatment.

Updates on the national performance benchmarks for digital mammography.

Early-stage breast cancer patients with low muscle quality and quantity have twice the risk of hospitalization.

African American patients are more likely to be diagnosed with advanced cancer and have higher mortality.

Premenopausal African American women with a p35 mutation may be at a higher risk of developing breast cancer.

Combination treatment helped increase invasive disease-free survival in patients with an aggressive type of early breast cancer.

Researchers create a map of breast cancer cell shapes and genes that is linked to outcomes.

Mapping cancer cells to genes helps to formulate a treatment plan.

Lynparza (olaparib) shows efficacy in a phase 3 clinical trial of BRCA-mutated HER2-negative metastatic breast cancer.

The phase 3 OLYMPIAD clinical trial met its primary endpoint of progression-free survival in breast cancer.

Certain BRCA1 mutations reduce the risk of developing leukemia.

Top news of the day from across the health care landscape.